JP2005527570A - 肺障害の治療 - Google Patents

肺障害の治療 Download PDF

Info

Publication number
JP2005527570A
JP2005527570A JP2003581716A JP2003581716A JP2005527570A JP 2005527570 A JP2005527570 A JP 2005527570A JP 2003581716 A JP2003581716 A JP 2003581716A JP 2003581716 A JP2003581716 A JP 2003581716A JP 2005527570 A JP2005527570 A JP 2005527570A
Authority
JP
Japan
Prior art keywords
atiii
antithrombin iii
lung
lung injury
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003581716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527570A5 (enExample
Inventor
和憲 村上
エンカバータル，ペレンレイ
ディー トレイバー，リリアン
エス プロフ，ドナルド
エヌ ハーンドン，デイヴィッド
エル トレイバー，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
rEVO Biologics Inc
Original Assignee
GTC Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTC Biotherapeutics Inc filed Critical GTC Biotherapeutics Inc
Publication of JP2005527570A publication Critical patent/JP2005527570A/ja
Publication of JP2005527570A5 publication Critical patent/JP2005527570A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003581716A 2002-04-01 2003-03-25 肺障害の治療 Pending JP2005527570A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36899702P 2002-04-01 2002-04-01
PCT/US2003/009053 WO2003084476A2 (en) 2002-04-01 2003-03-25 Treatment of lung disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011176604A Division JP2011225625A (ja) 2002-04-01 2011-08-12 肺障害の治療

Publications (2)

Publication Number Publication Date
JP2005527570A true JP2005527570A (ja) 2005-09-15
JP2005527570A5 JP2005527570A5 (enExample) 2006-05-25

Family

ID=29420316

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003581716A Pending JP2005527570A (ja) 2002-04-01 2003-03-25 肺障害の治療
JP2011176604A Withdrawn JP2011225625A (ja) 2002-04-01 2011-08-12 肺障害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011176604A Withdrawn JP2011225625A (ja) 2002-04-01 2011-08-12 肺障害の治療

Country Status (10)

Country Link
US (1) US20090221475A9 (enExample)
EP (1) EP1494696A4 (enExample)
JP (2) JP2005527570A (enExample)
KR (2) KR20040105838A (enExample)
CN (1) CN100384469C (enExample)
AU (3) AU2003233428B2 (enExample)
CA (1) CA2480790A1 (enExample)
IL (2) IL164078A0 (enExample)
NZ (1) NZ535487A (enExample)
WO (1) WO2003084476A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024509735A (ja) * 2021-02-17 2024-03-05 ユニヴァーシティ オヴ ロチェスター 敗血症の予後を処置、診断及び予測する方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
WO2012051339A2 (en) * 2010-10-12 2012-04-19 Vetgel Technologies Methods and compositions for treating respiratory conditions using platelet enriched plasma
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
US10174110B2 (en) 2013-02-13 2019-01-08 Laboratoire Français Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-α antibodies and uses thereof
WO2014140927A2 (en) 2013-02-13 2014-09-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
KR20160029840A (ko) 2013-07-05 2016-03-15 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 친화성 크로마토그래피 매트릭스
JP6779866B2 (ja) 2014-06-13 2020-11-04 チルドレンズ メディカル センター コーポレイション ミトコンドリアを単離するための製品および方法
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
WO2020214644A1 (en) * 2019-04-15 2020-10-22 Children's Medical Center Corporation Aerosolized compositions comprising mitochondria and methods of use thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63132843A (ja) * 1986-11-22 1988-06-04 Green Cross Corp:The 抗炎症剤
JPH06256213A (ja) * 1993-03-03 1994-09-13 Green Cross Corp:The ヒト由来アンチトロンビン−ｉｉｉの医薬用途
WO1995031207A1 (en) * 1994-05-13 1995-11-23 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
JPH09176040A (ja) * 1995-12-27 1997-07-08 Green Cross Corp:The ヘパリンコファクターｉｉの医薬用途
JP2000501082A (ja) * 1995-11-30 2000-02-02 ハミルトン シビック ホスピタルズ リサーチ デベロップメント，インコーポレイテッド グリコサミノグリカン―アンチトロンビンｉｉｉ／ヘパリン補因子ｉｉ結合体
WO2000023569A1 (en) * 1998-10-20 2000-04-27 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
WO2001080633A2 (en) * 2000-04-26 2001-11-01 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
WO2002022150A2 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes antithrombin iii
JP2003040797A (ja) * 2001-07-06 2003-02-13 Aventis Behring Gmbh 抗炎症性肺疾患およびａｒｄｓにおける抗トロンビン吸入のための医薬製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4117078A1 (de) * 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
AU2002224408B2 (en) * 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63132843A (ja) * 1986-11-22 1988-06-04 Green Cross Corp:The 抗炎症剤
JPH06256213A (ja) * 1993-03-03 1994-09-13 Green Cross Corp:The ヒト由来アンチトロンビン−ｉｉｉの医薬用途
WO1995031207A1 (en) * 1994-05-13 1995-11-23 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
JP2000501082A (ja) * 1995-11-30 2000-02-02 ハミルトン シビック ホスピタルズ リサーチ デベロップメント，インコーポレイテッド グリコサミノグリカン―アンチトロンビンｉｉｉ／ヘパリン補因子ｉｉ結合体
JPH09176040A (ja) * 1995-12-27 1997-07-08 Green Cross Corp:The ヘパリンコファクターｉｉの医薬用途
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
WO2000023569A1 (en) * 1998-10-20 2000-04-27 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
WO2001080633A2 (en) * 2000-04-26 2001-11-01 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
WO2002022150A2 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes antithrombin iii
JP2003040797A (ja) * 2001-07-06 2003-02-13 Aventis Behring Gmbh 抗炎症性肺疾患およびａｒｄｓにおける抗トロンビン吸入のための医薬製剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024509735A (ja) * 2021-02-17 2024-03-05 ユニヴァーシティ オヴ ロチェスター 敗血症の予後を処置、診断及び予測する方法

Also Published As

Publication number Publication date
WO2003084476A2 (en) 2003-10-16
IL164078A0 (en) 2005-12-18
CN1774258A (zh) 2006-05-17
IL164078A (en) 2011-02-28
KR20040105838A (ko) 2004-12-16
US20040192595A1 (en) 2004-09-30
AU2011236070A1 (en) 2011-11-03
EP1494696A2 (en) 2005-01-12
CN100384469C (zh) 2008-04-30
NZ535487A (en) 2008-12-24
US20090221475A9 (en) 2009-09-03
AU2003233428A1 (en) 2003-10-20
CA2480790A1 (en) 2003-10-16
KR20100117148A (ko) 2010-11-02
EP1494696A4 (en) 2006-01-25
WO2003084476A3 (en) 2004-04-22
JP2011225625A (ja) 2011-11-10
AU2008243077A1 (en) 2008-11-27
AU2003233428B2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
JP2011225625A (ja) 肺障害の治療
AU2022241504B2 (en) Methods of administering high concentrations of nitric oxide
Leversha et al. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma
LV12201B (en) USE OF NITROGEN OXIDE FOR BRONHOSTENOSE TREATMENT OR PROFILE
JPH05501263A (ja) グルタチオンのエーロゾル製剤
EP2825179B1 (en) Methods of administering high concentrations of nitric oxide
Soler et al. A bradykinin-antagonist blocks antigen-induced airway hyperresponsiveness and inflammation in sheep
O'Doherty et al. Nebuliser therapy in the intensive care unit
AU2021326382B2 (en) Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
KR20130055580A (ko) 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
HK1087930A (en) Treatment of lung disorder
Ibrahim et al. Inhaled Therapy for Other Respiratory Diseases: Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis
JP2025506019A (ja) トレプロスチニルイロプロスト併用療法
HK40072978A (en) Methods of administering high concentrations of nitric oxide
WO2022118220A1 (en) Compositions, devices, and methods for treating respiratory disorders
RS66259B1 (sr) Primena dalargina za prevenciju virusnih respiratornih infekcija i prevenciju razvoja komplikacija tokom virusnih respiratornih infekcija
Challoner Aerosol delivery of antibiotics
Knowles et al. NEW INDICATIONS FOR THERAPEUTIC AEROSOLS
Inhaler Nebulized Wet Aerosol Treatment in Emergency Department—Is It Essential?
HK1206255B (en) Methods of administering high concentrations of nitric oxide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090813

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090925

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091022

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110412

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110812

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110826

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110930